Two more recent reports with PLD/VNB combination as first-line tr

Two more recent reports with PLD/VNB combination as first-line treatment in elderly patients confirmed the good overall clinical response rate (36% and 50%, respectively), and the high tolerability of the regimen [39, 40] suggesting, due to the safety profile of the combination, the employment also in such “”frail”" patient population. An increasingly pertinent question in patients relapsing following adjuvant anthracyclines is whether there is a role for anthracycline rechallenge in those with a long free-interval. As a

result of a high cardiac risk associated with increasing cumulative anthracycline dose, patients are often denied re-treatment in advanced setting; the LY3023414 supplier choice of a liposomal anthracycline allows the possibility of re-treating an anthracycline-responsive disease without substantially increasing the cardiac risk [36]; this option should not be excluded in fact, and some evidences come from a recent report on first- line chemotherapy selection in adjuvant anthracycline-pretreated

patients, where no differences have been found between CMF-based and anthracycline-containing Torin 1 cost regimens for their impact on the outcome of first-line anthracycline treatment [41]. By this point of view, even if our results are in anthracycline-naïve patients, the activity and the low toxicity profile observed suggest that the choice of a liposomal formulation can offer the chance of a more tolerable regimen maintaing conventional anthracyclines efficacy. The results

of the present trial indicated both EPI/VNB and PLD/VNB as two reasonable choices as first-line treatment for women with relapsed breast cancer not previously treated with adjuvant anthracyclines; since advanced breast cancer is still an incurable disease, the goals of treatments are symptoms palliation with minimal toxicity, and survival prolongation, possibly with regimens active against cancer but also preserving patient’s quality of life; in this context, our results are encouraging, confirming the feasibility and efficacy of two anthracycline-containing regimens and, particularly, of a regimen devoided of cardiac toxicity and of other severe side effects, such as PLD/VNB; the choice of fantofarone this combination could offer a better quality of life and, hopefully, a better outcome to metastatic breast cancer patients. Conclusions Both anthracycline-based regimens evaluated as first-line treatment in advanced breast cancer patients not previously treated with anthracyclines seems to be active and well tolerated, and can be considered as a reasonable choice in this subset of patients References 1. Hamilton A, Hortobagyi G: Chemotherapy: what progress in the last 5 years? J Clin Oncol 2005, 23:1760–1775.PubMedCrossRef 2.

Comments are closed.